The Sanyal Phase 2a in MASLD examined 98 adults with metabolic dysfunction-associated steatotic liver disease and 10 percent liver fat content, randomised to retatrutide or placebo over 48 weeks
The rate gradually slowed as participants approached week 40 to 48, when most reached a natural plateau
Our major concern is the unbalance and inappropriate reductions in calorie or energy intake associated with these weight loss drugs," said Cooper, associate director of the UCI Institute for Clinical and Translational Science and interim director of the UCI Institute for Precision Health
Meanwhile, support your metabolism and wellness with our quick-access supplements like GLP-1 Daily Support and Weight Loss Boost available now without a quiz
For instance, medications that speed gastric emptying may partially counteract some effects, while those that slow it may intensify side effects
This makes them ideal multi-condition solutions